Isradipine

Isradipine
Clinical data
Trade namesDynaCirc
AHFS/Drugs.comMonograph
MedlinePlusa693048
Pregnancy
category
  • C
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability15-24%
Protein binding95%
Metabolism100% Hepatic
Elimination half-life8 hours
Excretion70% Renal, 30% Fecal
Identifiers
  • 3-Methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.158.721 Edit this at Wikidata
Chemical and physical data
FormulaC19H21N3O5
Molar mass371.393 g·mol−1
3D model (JSmol)
  • O=C(OC)\C3=C(\N\C(=C(\C(=O)OC(C)C)C3c1cccc2nonc12)C)C
  • InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3 checkY
  • Key:HMJIYCCIJYRONP-UHFFFAOYSA-N checkY
  (verify)

Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack.

It was patented in 1978 and approved for medical use in 1989.[1]

Medical uses

Isradipine is given as either a 2.5 mg or 5 mg capsule.[2]

Side effects

Common side effects include:[3]

  • Dizziness
  • Warmth, redness, or tingly feeling under your skin
  • Headache
  • Weakness, tired feeling
  • Nausea, vomiting, diarrhea, upset stomach
  • Skin rash or itching

Serious side effects include:[3]

  • Lightheadedness or fainting
  • Shortness of breath, especially from minimal physical activity
  • Swelling in the hands and feet
  • Rapid and/or heavy heartbeat
  • Chest pain

Drug interactions

It is advised that those using isradipine not take dolasetron (Anzemet), as both agents can cause a dose-dependent PR interval and QRS complex prolongation.[4]

Itraconazole (Onmel/Sporanox) exhibits a negative inotropic effect on the heart and thus could spur an additive effect when used concomitantly with isradipine. Itraconazole also inhibits an important cytochrome liver enzyme (CYP 450 3A4) which is needed to metabolize isradipine and other calcium channel blockers. This will increase plasma levels of isradipine and could cause an unintentional overdose of the medication. Caution is advised when administering both agents together.[5]

Tizanidine demonstrates anti-hypertensive effects and should be avoided in patients taking isradipine due to the possibility of synergism between both medications.[6]

The antibiotic rifampin lowered plasma concentrations of isradipine to below detectable limits.[2]

Cimetidine increased isradipine mean peak plasma levels. A downward dose adjustment may be necessary with this particular instance of polypharmacy.[2]

Severe hypotension was reported with fentanyl anesthesia when it was combined with other calcium channel blockers. Even though isradipine, another calcium channel blocker, has not been used in conjunction with fentanyl anesthesia in any studies, caution is advised.[2]

Overdose

Symptoms of an isradipine overdose include:[2]

Stereochemistry

Isradipine contains a stereocenter and consists of two enantiomers, more precisely atropisomers. This is a racemate, i.e. a 1: 1 mixture of (R)- and the (S)-forms:[7]

Enantiomers of Isradipine

CAS-Nummer: 84260-63-9
CAS-Nummer: 84260-64-0

References

  1. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 465. ISBN 9783527607495.
  2. ^ a b c d e "Isradipine: Brands, Medical Use, Clinical Data". Archived from the original on 2019-09-13. Retrieved 2013-01-21.
  3. ^ a b "Isradipine Side Effects".
  4. ^ "Isradipine and Anzemet Drug Interactions".
  5. ^ "Isradipine and Onmel Drug Interactions".
  6. ^ "Isradipine and Zanaflex Drug Interactions".
  7. ^ Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, ISBN 978-3-946057-10-9, S. 193.

Further reading